Promacta (Eltrombopag Olamine) Patent Expiration, LOE Window & CMS Spending

Promacta (Eltrombopag Olamine) by Novartis: FDA Orange Book core substance LOE 2026-01-13, 10 AB generics, $902.7M 2024 CMS Part D & Medicaid spend, and 21 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN022291 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2026-01-13
Last Listed Patent or Exclusivity Date2026-01-13
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$902.7M
2024 Medicare Part D Spend$672.4M
2024 Medicaid Spend$230.3M
Reported Wholesale Price Change (CA SB 17)21 WAC filings (max 28.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.